OCCIDENT participates in Tubulis’ Series C financing round of €308 million, led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital.
Besides OCCIDENT, existing investors who supported the Series C include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF) and Seventure Partners.
Tubulis develops novel antibody-drug conjugates (ADCs) for the targeted and effective treatment of cancer and other diseases.
The proceeds from the Series C financing will be used to expand the clinical development of TUB-040, Tubulis’ lead antibody-drug conjugate (ADC) candidate, into earlier lines of therapy and additional tumor indications. TUB-040 targets NaPi2b, an antigen that is overexpressed in ovarian cancer and lung adenocarcinomas. TUB-040 is currently being evaluated in a Phase I/IIa study in patients with platinum-resistant ovarian cancer (PROC) as well as relapsed or refractory non-small cell lung cancer and was granted Fast Track designation by the U.S. FDA in June 2024. The capital will also advance Tubulis’ pipeline, including the clinical-stage ADC candidate TUB-030, several preclinical programs, and expand its proprietary ADC platform technologies to bring ADCs into novel applications.
Congratulations to the entire team on this great success! We are very much looking forward to the next exciting steps in the company’s development.
Further information can be found in the press release at the following link.
More about Tubulis
